Ikram Joubair
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ikram Joubair has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Ismaïl Moukadiri
Engineering School in Biomedical and Biotechnology, Euromed University of Fes, Eco-Campus UEMF, Route de Meknes (RN6, Rond-Point Bensouda), Fez 30070, Morocco
2 shared publications - Jesús Zueco
Unidad de Microbiología, Facultad de Farmacia, Universidad de Valencia, Avda. Vicente Andrés Estelles s/n, Burjassot, 46100 Valencia, Spain
2 shared publications - Ouafaa Fassi Fihri
Pathology and Veterinary Public Health Department, Institut Agronomique et Vétérinaire HASSAN II, P.O. Box 6202, Rabat 10000, Morocco
2 shared publications - Salim Bounou
Euromed Faculty of Pharmacy, Euro-Mediterranean University of Fes, Fes, Morocco, Morocco
2 shared publications - Abdellatif Errabbani
Engineering School in Biomedical & Biotechnology, Euromed Faculty of Pharmacy, Euro-Mediterranean University of Fez, Eco-Campus UEMF, Route de Meknes (RN6, Rond-Point Bensouda), Fez 30070, Morocco
1 shared publication - Guillem Montalban-Faet
Department of Computer Science, University of Valencia, Valencia, Spain, Spain
1 shared publication
Latest Publications
- Open Access
- 23 October 2026
- Published by MDPI AG in Preprints.org
Reverse Vaccinology and Immunoinformatics-Based Design of Serotype-Specific and Multiserotype Multi-Epitope Vaccine Candidates Against Bluetongue Virus Serotypes 1, 3, 4, and 8 Circulating in the Mediterranean Basin
Bluetongue is an economically important arboviral disease affecting domestic and wild ruminants health and well-being, caused by bluetongue virus (BTV) and transmitted by Culicoides midges. More than 30 BTV serotypes may co-circulate regionally, while current vaccines face limitations related to safety and incomplete cross-protection. Here, reverse vaccinology and immunoinformatics were used to design four serotype-specific and one multiserotype multi-epitope vaccine candidates targeting BTV-1, BTV-3, BTV-4 and BTV-8. Cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes were predicted from VP2, VP5, VP7 and NS1, and linear B-cell epitopes from VP2 and VP5. Twenty-five CTL, 24 HTL and 15 B-cell epitopes met the computational antigenicity, non-allergenicity and non-toxicity screening criteria; HTL epitopes were also predicted to induce interferon-γ. Five constructs comprising 13-25 epitopes (252-471 amino acids) were fused to bovine β-defensin 2 as a putative adjuvant. Molecular docking with bovine Toll-like receptor 4 ectodomain yielded predicted binding energies ranging from -19.6 to -10.7 kcal/mol. Molecular dynamics simulations (100 ns), immune simulation, codon optimization and in silico cloning further characterized the candidates. These computational findings support the prioritization of these constructs for experimental evaluation as potential serotype-specific and multiserotype BTV vaccine candidates.
- 23 October 2026
- Published by MDPI AG in Preprints.org
Open AccessReverse Vaccinology and Immunoinformatics-Based Design of Serotype-Specific and Multiserotype Multi-Epitope Vaccine Candidates Against Bluetongue Virus Serotypes 1, 3, 4, and 8 Circulating in the Mediterranean Basin
Bluetongue is an economically important arboviral disease affecting domestic and wild ruminants health and well-being, caused by bluetongue virus (BTV) and transmitted by Culicoides midges. More than 30 BTV serotypes may co-circulate regionally, while current vaccines face limitations related to safety and incomplete cross-protection. Here, reverse vaccinology and immunoinformatics were used to design four serotype-specific and one multiserotype multi-epitope vaccine candidates targeting BTV-1, BTV-3, BTV-4 and BTV-8. Cytotoxic T-lymphocyte (CTL) and helper T-lymphocyte (HTL) epitopes were predicted from VP2, VP5, VP7 and NS1, and linear B-cell epitopes from VP2 and VP5. Twenty-five CTL, 24 HTL and 15 B-cell epitopes met the computational antigenicity, non-allergenicity and non-toxicity screening criteria; HTL epitopes were also predicted to induce interferon-γ. Five constructs comprising 13-25 epitopes (252-471 amino acids) were fused to bovine β-defensin 2 as a putative adjuvant. Molecular docking with bovine Toll-like receptor 4 ectodomain yielded predicted binding energies ranging from -19.6 to -10.7 kcal/mol. Molecular dynamics simulations (100 ns), immune simulation, codon optimization and in silico cloning further characterized the candidates. These computational findings support the prioritization of these constructs for experimental evaluation as potential serotype-specific and multiserotype BTV vaccine candidates.
- Open Access
- 12 February 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (2) , 437
Bluetongue in the Mediterranean Basin: An Overview of Recent Hotspots and Advances in Vaccine Technologies
Bluetongue (BT) is a noncontagious, arthropod-borne viral disease of domestic and wild ruminants caused by bluetongue virus (BTV), an arbovirus of the Orbivirus genus within the Sedoreoviridae family. At least 36 serotypes have been identified globally; recurrent circulation of BTV-1, -4, and -8, along with the recent emergence of BTV-3 in northern Europe, underscores a persistent incursion risk for Mediterranean herds. Key drivers include climate-driven expansion of Culicoides vector niches, windborne dispersal, animal movements, and subclinical reservoirs in cattle and goats. As no specific treatment is currently available, control of bluetongue disease still relies largely on vaccination. Live-attenuated vaccines and inactivated vaccines have reduced incidence, but important limitations persist: risk of reversion and the possibility of reassortment for LAVs; requirement for multiple doses and limited cross-protection for inactivated products; and the absence of DIVA capability for both. As an alternative, next-generation platforms are under active evaluation. Subunit formulations, often VP2 combined with VP5 and/or NS1/NS2 virus-like particles (VLPs), and viral-vectored constructs demonstrate favorable safety, strong humoral and cellular responses, inherent or engineered DIVA compatibility, and potential for rapid updating against emergent serotypes. This review synthesizes recent bluetongue activity across the Mediterranean Basin and provides a critical assessment of both existing and emerging vaccine strategies, with a focus on recommending next-generation platforms that emphasize DIVA-compliant, multiserotype, and adaptable vaccination approaches, supported by integrated surveillance and vector control in the region.
- 12 February 2026
- Published by MDPI AG in Microorganisms
- Vol. 14 (2) , 437
Open AccessBluetongue in the Mediterranean Basin: An Overview of Recent Hotspots and Advances in Vaccine Technologies
Bluetongue (BT) is a noncontagious, arthropod-borne viral disease of domestic and wild ruminants caused by bluetongue virus (BTV), an arbovirus of the Orbivirus genus within the Sedoreoviridae family. At least 36 serotypes have been identified globally; recurrent circulation of BTV-1, -4, and -8, along with the recent emergence of BTV-3 in northern Europe, underscores a persistent incursion risk for Mediterranean herds. Key drivers include climate-driven expansion of Culicoides vector niches, windborne dispersal, animal movements, and subclinical reservoirs in cattle and goats. As no specific treatment is currently available, control of bluetongue disease still relies largely on vaccination. Live-attenuated vaccines and inactivated vaccines have reduced incidence, but important limitations persist: risk of reversion and the possibility of reassortment for LAVs; requirement for multiple doses and limited cross-protection for inactivated products; and the absence of DIVA capability for both. As an alternative, next-generation platforms are under active evaluation. Subunit formulations, often VP2 combined with VP5 and/or NS1/NS2 virus-like particles (VLPs), and viral-vectored constructs demonstrate favorable safety, strong humoral and cellular responses, inherent or engineered DIVA compatibility, and potential for rapid updating against emergent serotypes. This review synthesizes recent bluetongue activity across the Mediterranean Basin and provides a critical assessment of both existing and emerging vaccine strategies, with a focus on recommending next-generation platforms that emphasize DIVA-compliant, multiserotype, and adaptable vaccination approaches, supported by integrated surveillance and vector control in the region.